Uncategorized

As part of Lupus Awareness Month, May 1 has been declared “Lupus Call to Action Day” by the National Minority Health Association (NMHA) and members of the lupus community. Kicking off at NYU Langone Health in New York City, the high-profile platform is designed to drive awareness and enact change to improve equity and inclusion … On “Lupus Call to Action Day”, the Lupus Research Alliance and Lupus Therapeutics Amplify a Call for Equity and Inclusion

Lupus Therapeutics, the clinical research affiliate of the Lupus Research Alliance, has announced an innovative expansion of the highly successful Patient Advocates for Lupus Studies (PALS) program with the introduction of a first-in-lupus “Trial Buddy” component made possible by a partnership with Bristol Myers Squibb. The Trial Buddy addition provides extra support to people with … Lupus Peer-to-Peer Early Education Program Expands

At the recent ACR Convergence 2023, the annual meeting of the American College of Rheumatology, important lupus clinical trial data and breakthrough foundational research were presented. Following are highlights of work funded by the Lupus Research Alliance or supported in partnership with industry through our clinical affiliate Lupus Therapeutics. CAR-T Cell Therapy is Showing Great … Summary Highlights of Important Research Presented at ACR Convergence 2023

The LRA and our clinical arm Lupus Therapeutics are pleased to share good news from Cabaletta Bio, Inc. that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for CABA-201, a CAR T cell investigational therapy in development to treat systemic lupus erythematosus and lupus nephritis – a common lupus complication causing … Investigational CAR T Cell Gets Fast Tracked by U.S. FDA

We are excited to share good news – our Lupus Clinical Investigators Network, LuCIN, managed by LRA’s affiliate Lupus Therapeutics, will be working on a new research project to increase diverse representation of patients in lupus trials to be funded with a $500,000 National Institutes of Health Innovation Award from the Food and Drug Administration’s … NIH Awards $500,000 to Advance to Advance Diversity in Lupus Trials

We are pleased to share positive results from the two-part Phase 2 LILAC study published in the New England Journal of Medicine showing that the investigational therapy litifilimab (BIIB059) lessened skin disease activity in cutaneous lupus erythematosus. There is a great unmet need for people with cutaneous lupus, a type of lupus with few treatment options that … New England Journal of Medicine Publishes Positive Data of Litifilimab in Cutaneous Lupus Erythematosus

Advocating for your own best care includes raising the possibility of joining a clinical trial with your healthcare provider.  Here’s more on how: It is important for individuals who are considering participation in a trial to understand what will be involved.  The National Institutes of Health (NIH) asking the healthcare team overseeing the study about … Ask About Clinical Trial Opportunities

Up to 95% of lupus patients report pain and fatigue caused by the disease. To explore ways to fix this, a research team led by Dr. Cynthia Aranow at The Feinstein Institutes for Medical Research studied whether lessening inflammation in patients with lupus would also lessen pain and fatigue. In this study, she and her … LuCIN Investigators Show that Stimulating the Vagus Nerve in Lupus Patients Decreases Pain and Fatigue

Results of clinical trials testing potential lupus treatments were highlighted at the American College of Rheumatology’s annual meeting ACR Convergence 2020. These studies include phase I trials, which test for side effects and a safe dosage; larger phase II trials, which test for effectiveness and further gauge safety; and large phase III trials, which confirm … Promising New Lupus Treatments Highlighted ACR Annual Meeting